Drug Development and Industrial Pharmacy is a prestigious journal published by Taylor & Francis Ltd, focusing on the critical field of pharmaceutical sciences. With an ISSN of 0363-9045 and an E-ISSN of 1520-5762, the journal has been an essential resource for researchers and professionals since its inception in 1974. It occupies a crucial niche within Drug Discovery, Organic Chemistry, and Pharmaceutical Science, currently ranked in the second and third quartiles, reflecting its solid contribution to the field. The journal encompasses a wide array of topics, including drug development processes, formulation, and industrial manufacturing alongside cutting-edge research in pharmacology and toxicology. With a commendable Scopus ranking demonstrating high relevance—ranked #44 in Pharmaceutical Science—it serves as a vital forum for academia and industry to share innovative findings and methodologies. While it does not offer open access, the journal remains an invaluable resource for those seeking to advance their knowledge and enhance their research in pharmaceutical development.

Journal of Pharmaceutical Investigation, published by SPRINGERNATURE, is a leading academic resource in the field of pharmaceutical sciences, offering critical insights and innovative research findings. With an impact factor that underscores its significance, this journal ranks in the Q1 category for both Pharmacology and Pharmaceutical Science as of 2023, showcasing its high-quality publications and rigorous peer-review processes. Operating from the Netherlands, the journal spans from 2012 to 2024, offering a rich archive of interdisciplinary research contributions that advance knowledge in pharmacology, toxicology, and pharmaceutics. It holds impressive Scopus rankings, placing it among the top-tier journals in its categories, which enhances its appeal to researchers, professionals, and students aiming to publish their work or stay up-to-date with the latest advancements in the pharmaceutical field. Engaging with the Journal of Pharmaceutical Investigation not only enriches your understanding but also connects you with a community dedicated to advancing healthcare and therapeutic innovations.

Drug Delivery and Translational Research (ISSN: 2190-393X | E-ISSN: 2190-3948), published by Springer Heidelberg, stands at the forefront of the Pharmaceutical Sciences discipline, boasting a prestigious impact factor as evidenced by its Q1 category ranking in 2023. This esteemed journal is dedicated to the vital intersection of drug delivery systems and translational research, aiming to bridge the gap between laboratory findings and clinical applications. It features groundbreaking studies that enhance our understanding of drug pharmacokinetics, formulations, and patient-centered research, making it indispensable for researchers, professionals, and students striving to innovate and excel in the field. While the journal operates under a subscription model, its commitment to disseminating high-quality research is reflected in its Scopus rank, placing it in the top 6% of its category (Rank #11/183, 94th percentile). Since its inception in 2011, it has garnered significant attention, promoting advances in pharmacology, toxicology, and pharmaceutics, and continues to be a platform for vital discourse and discovery.

Artificial Cells Nanomedicine and Biotechnology is a prestigious peer-reviewed journal published by TAYLOR & FRANCIS LTD, specializing in the rapidly evolving fields of biomedical engineering, biotechnology, and nanomedicine. Established in 2013 and operating under an open-access model since 2019, the journal aims to bridge the gap between fundamental science and real-world medical applications, showcasing cutting-edge research that advances our understanding of artificial cells and their biotechnological applications. With an impressive impact factor and ranking in the Q2 quartile across various categories, including Biomedical Engineering, Medicine, and Pharmaceutical Sciences, the journal is a leading platform for innovative studies that contribute significantly to the realm of healthcare and therapeutic development. Researchers, professionals, and students alike will find invaluable insights and advancements within its pages, positioning it as a vital resource for those dedicated to pushing the boundaries of science and improving patient outcomes.

International Journal of Pharmaceutical Investigation, published by INPHARM ASSOC, PHCOG NET, is a premier platform dedicated to advancing the field of pharmaceutical sciences. With the ISSN 2230-973X and E-ISSN 2230-9713, this journal serves as a vital resource for researchers, professionals, and students focused on drug development, formulation, and efficacy. By fostering a rich discourse on innovative pharmaceutical practices and research breakthroughs, the journal plays a critical role in enhancing global health outcomes through groundbreaking scholarly work. The absence of open access allows for selective dissemination of high-quality content, promoting rigorous peer-review processes that uphold academic integrity. Featuring articles that span a diverse range of topics within pharmaceutical sciences, the International Journal of Pharmaceutical Investigation is committed to supporting the ongoing evolution of this dynamic field, making it an essential read for anyone engaged in pharmaceutical research and development.

JOURNAL OF CONTROLLED RELEASE is a premier academic journal published by Elsevier that is dedicated to advancing the field of pharmaceutical science with a focus on drug delivery systems. Established in 1984, the journal has consistently served as a vital platform for disseminating high-quality research and innovative ideas in the area of controlled release technologies. With an impressive impact factor and ranking in the Q1 category of Pharmaceutical Science, it ranks #3 out of 183 in Scopus for its field, reflecting its influence and significance within the academic community, as noted by its percentile of 98th. The journal encompasses a wide range of topics, including polymer science, pharmacokinetics, and bioengineering, ensuring it remains at the forefront of pharmaceutical advancements. While currently not offering open access options, the journal serves a diverse audience of researchers, professionals, and students who are eager to push the boundaries of knowledge in drug delivery and therapeutics. For those looking to make impactful contributions in this dynamic field, JOURNAL OF CONTROLLED RELEASE is an essential resource for both foundational studies and cutting-edge research findings.

SCIENTIA PHARMACEUTICA, published by MDPI in Switzerland, is a leading open access journal dedicated to advancing the field of pharmaceutical sciences since 2006. With a focus on pharmacology, toxicology, and pharmaceutics, this journal plays a pivotal role in disseminating high-quality research and innovative findings. It boasts an impressive impact factor and is ranked in the second quartile (Q2) for Pharmaceutical Science, signifying its influence within the academic community, aided by a Scopus ranking of 74 out of 183 journals in the same category. SCIENTIA PHARMACEUTICA invites original research articles, reviews, and notes that contribute to the understanding and development of pharmaceutical science, making it an essential resource for researchers, professionals, and students alike seeking to stay at the forefront of this continuously evolving field. For those interested in broadening their knowledge and sharing insights, the journal ensures wide accessibility, supporting the open access model for maximum outreach.

Cancer Nanotechnology is a cutting-edge peer-reviewed journal dedicated to advancing the field of cancer research through innovative nanotechnology applications. Published by SPRINGER WIEN, this open-access journal, established in 2010, provides a vital platform for the dissemination of high-quality research with a focus on the intersection of nanotechnology, oncology, and biomedical engineering. With a commitment to promoting accessibility and fostering collaboration, Cancer Nanotechnology has gained impressive rankings within specialized categories, including Q2 in Biomedical Engineering and Pharmaceutical Science. The journal's rigorous selection process ensures that only the most impactful studies reach its audience, making it a must-read for researchers, professionals, and students eager to explore the latest advancements and methodologies in cancer treatment. With its scope encompassing critical topics that bridge multiple disciplines—including physical chemistry and toxicology—Cancer Nanotechnology positions itself as an influential resource for shaping the future of cancer therapies.

Nanomedicine, published by Future Medicine Ltd, is a premier academic journal dedicated to the rapidly evolving field of nanotechnology in medicine. With an emphasis on innovative research and applications, this journal encompasses a broad spectrum of topics including bioengineering, biomedical engineering, and nanoscience, among others. Featuring an impressive Q1 ranking in Development and multiple Q2 rankings across significant categories, it serves as a pivotal resource for researchers and professionals aiming to stay at the forefront of advancements in these disciplines. While the journal is not open access, it is accessible through various institutional subscriptions, ensuring wide dissemination of cutting-edge findings. Notably, it has achieved substantial impact within the scientific community, indicated by its high rankings in Scopus and overall commitment to enhancing the understanding and application of nanomedicine. This journal is a vital conduit for fostering collaborations and innovations that transcend traditional medical paradigms.

CURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.